Future combination of Heme arginate and LPV/RTV or drugs that are not metabolized by CYP2D6/3A4 might have a synergy as an efficacious dual drug-therapy to counteract the severe inflammation caused by COVID-19. This evidence concerns the gene CYP2D6 and COVID-19.